FDA Approves Targeted RNA-based Therapy to Treat Rare Disease

The U.S. Food and Drug Administration recently approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidoisis (hATTR) in adult patients. This rare debilitating and often fatal genetic disease is characterized by the buildup of abnormal amyloid protein in peripheral nerves, the heart and other organs. Onpattro is…

The post FDA Approves Targeted RNA-based Therapy to Treat Rare Disease appeared first on Burke Harvey, LLC | Injury & Accident Lawyers in Birmingham, Alabama.